Comprehensive longevity science knowledge base covering the 2023-2025 research landscape: 12 hallmarks of aging, therapeutic interventions, biomarkers, clinical trials, industry landscape, and an interactive D3.js mindmap.
Open longevity_mindmap.html in any modern browser for an interactive radial tree visualization of the entire knowledge base.
- 6 color-coded branches with 100+ data nodes
- Click to expand/collapse, hover for detailed tooltips
- Zoom (scroll) and pan (drag) navigation
- Key data points: lifespan extension %, trial results, funding amounts
Longevity/
├── longevity_mindmap.html # Interactive D3.js radial mindmap
├── longevity_research_review.md # Full research review (1,696 lines)
├── longevity-research-tracker-prompts.md # 3-phase prompt methodology
│
├── research_notes/ # Phase 1: Raw research findings
│ ├── hallmarks_findings.md # 12 Hallmarks of Aging (comprehensive)
│ ├── hallmarks_first_six_detailed.md # Detailed analysis of hallmarks 1-6
│ ├── biomarkers_clocks.md # Epigenetic, proteomic & functional clocks
│ ├── clinical_trials.md # 33+ clinical trials catalog
│ ├── companies_landscape.md # 25+ company profiles
│ ├── compounds_data.md # Intervention mechanisms & evidence
│ ├── key_publications.md # Key citations & references
│ ├── group1_epigenetic_reprogramming.md
│ ├── group2_glp1_agonists.md
│ ├── group3_mitochondrial_therapies.md
│ ├── group4_emerging_interventions.md
│ ├── group5_gene_therapies.md
│ ├── group6_plasma_young_blood.md
│ └── group7_inflammaging_targets.md
│
├── longevity_database/ # Phase 2: Structured CSV databases
│ ├── README_database.md # Schema documentation
│ ├── interventions_database.csv # 33 compounds with mechanisms & evidence
│ ├── clinical_trials_database.csv # 44 trials with NCT numbers & results
│ ├── companies_database.csv # 33 companies with funding & pipelines
│ ├── biomarkers_database.csv # 25 aging biomarkers & clocks
│ └── publications_database.csv # 66 key publications with citations
│
└── review_parts/ # Phase 3: Sectioned review drafts
├── sections_1_3.md
├── sections_4_5.md
└── sections_6_10.md
Genomic instability, telomere attrition, epigenetic alterations, loss of proteostasis, disabled macroautophagy, deregulated nutrient-sensing, mitochondrial dysfunction, cellular senescence, stem cell exhaustion, altered intercellular communication, chronic inflammation, and dysbiosis.
| Category | Key Compounds | Best Preclinical Result |
|---|---|---|
| Senolytics | D+Q, fisetin, UBX1325, navitoclax | ~36% remaining lifespan (D+Q) |
| mTOR Inhibitors | Rapamycin, everolimus, acarbose | 36.6% median lifespan (rapa+acarbose) |
| NAD+ Precursors | NMN, NR, CD38 inhibitors | NAD+ restoration, mixed clinical |
| GLP-1 Agonists | Semaglutide, tirzepatide | Epigenetic age reversal: GrimAge -3.1y |
| Epigenetic Reprogramming | OSK factors, SB000, chemical | 109% remaining lifespan (OSK) |
| Mitochondrial | Urolithin A, elamipretide | 12% muscle strength; FDA approval |
| Gene Therapy | Klotho, follistatin, SIRT6, TERT | 19.7-30% lifespan extension |
| Emerging | Taurine, GlyNAC, AKG, spermidine | 10-25% lifespan (taurine) |
- 1st generation: Horvath (2013), Hannum (2013)
- 2nd generation: PhenoAge (2018), GrimAge (2019)
- 3rd generation: DunedinPACE (2022) - measures rate of aging
- Proteomic: Organ-specific clocks (Oh et al. 2023), GDF-15
- Commercial: TruDiagnostic, Elysium, Tally Health, GlycanAge
33+ trials across 11 intervention classes. Key results include PEARL (rapamycin), ASPIRE (UBX1325, +5.6 letters in NEJM Evidence), MitoImmune (Urolithin A, Nature Aging 2025), and TAME (metformin, pending).
$8B+ invested across 25+ companies. Major players: Altos Labs ($3B), Retro Biosciences ($1B), Calico (Alphabet), Unity Biotechnology, Insilico Medicine. Pharma partnerships: AbbVie-Calico ($1.5B+), Novartis-BioAge, Lilly-BioAge.
- Peer-reviewed publications (Cell, Nature, Science, NEJM Evidence, Nature Aging, PNAS)
- ClinicalTrials.gov registrations
- Company disclosures and SEC filings
- Conference presentations (ASCO, ASH)
- Preprint servers (bioRxiv, medRxiv)
Evidence currency: through early 2025.
This project was built in 3 phases using Claude Code:
- Research & Data Collection - Systematic search across 12 hallmarks, 8 intervention categories, biomarkers, trials, and companies
- Database Construction - Structured CSV databases with standardized schemas
- Synthesis & Visualization - Comprehensive review document and interactive D3.js mindmap
See longevity-research-tracker-prompts.md for the full prompt methodology.
This is a research compilation for educational and informational purposes. All cited works belong to their respective authors and publishers.